Filters
Is radium-223 a universal drug of abone metastasis in castration-resistant prostate cancer?
Bone metastases in prostate cancer are a major cause of pain and bone complications. Radium-223 treatment of patients with bone metastasis in castration-resistant prostate cancer proved to be beneficial in prolonging overall surviva...
Oncology
- 2018 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Radium 223 in clinical praxes
. This therapy can reduce the extent of the disease and affect the quality of life. Radium 223 belongs to this type of therapy. We are presenting the case report of patient treated with radium 223....
Oncology
- 2020 •
- O
Rok uplatnění
O - Ostatní výsledky
Radium-223 dichloride (Xofigo) - management of the treatment of castration-resistant prostate cancer
, enzalutamid,sipuleucel-T and Ra-223 have shown improvement in survival in CRPC patients. Radium-223 dichloride is alpha-emitting radioisotope that targets areas......
FD - Onkologie a hematologie
- 2014 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Alpha emitter radium-223 and survival in metastatic prostate cancer
Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with place...
FD - Onkologie a hematologie
- 2013 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
The report on the clinical trial protocol number 16913
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second ...
FD - Onkologie a hematologie
- 2016 •
- Vutaj
Rok uplatnění
Vutaj - Výzkumná zpráva obsahující utajované informace
Radium 223 in clinical praxis
the dispatch of radiopharmaceuticals. Between this treatment line and radio 223 patients. We present a case report of a patient who was treated with radio 223....
Oncology
- 2019 •
- O
Rok uplatnění
O - Ostatní výsledky
Systemic radiotherapy for prostate cancer with bone metastases
radiotherapy. Most recently, an alpha emitter radium-223 has been introduced profile of radium-223 is very favorable with a minimal risk of serious hematologic......
FJ - Chirurgie včetně transplantologie
- 2016 •
- Jx •
- Link
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Výsledek na webu
Is age the limitation of metastatic treatment prostate cancer?
The median age of men with prostate cancer is 67,5 years. We have evidence-based information about elderly with metastaticprostate cancer in clinical trials. The age alone in not a contraindication for ARTA therapy (abiraterone acetate + prednisone,e...
Oncology
- 2018 •
- Jost
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Effect of mobile phase salinity on the Ac-227/Ra-223 generator
Radium-223 is the first approved alpha emitting radionuclide for use in radionuclide therapy [1]. Radium follows the Calcium metabolism and thus is self targeted addition into a mobile phase on Ac-227/Th-227/Ra-223...
CH - Jaderná a kvantová chemie, fotochemie
- 2014 •
- O
Rok uplatnění
O - Ostatní výsledky
Research of Radium Needles Processing for Recycling of Ra-226
for the construction of Ac-227 /Ra-223 radionuclide generator. Ra-226 would be recycled and reused in next irradiations. Ra-223 would then be used for the preparation of radiolabeled, a method for opening and processing the rad...
CH - Jaderná a kvantová chemie, fotochemie
- 2014 •
- O
Rok uplatnění
O - Ostatní výsledky
- 1 - 10 out of 504